Microbot Medical (NASDAQ:MBOT) Downgraded by ValuEngine to “Sell”

ValuEngine lowered shares of Microbot Medical (NASDAQ:MBOT) from a hold rating to a sell rating in a research report report published on Tuesday, ValuEngine reports.

Other research analysts have also issued reports about the company. Zacks Investment Research lowered Microbot Medical from a hold rating to a sell rating in a research report on Saturday, November 16th. HC Wainwright restated a buy rating and set a $10.00 target price on shares of Microbot Medical in a research report on Friday, November 22nd.

MBOT traded up $0.05 during trading on Tuesday, reaching $4.92. 17,244 shares of the stock traded hands, compared to its average volume of 31,131. The company has a quick ratio of 2.29, a current ratio of 2.29 and a debt-to-equity ratio of 0.02. The stock’s 50-day moving average is $4.96 and its 200 day moving average is $5.53. Microbot Medical has a 12 month low of $1.38 and a 12 month high of $19.40. The stock has a market capitalization of $21.41 million, a PE ratio of -2.04 and a beta of 4.99.

A number of institutional investors and hedge funds have recently modified their holdings of MBOT. JPMorgan Chase & Co. bought a new position in shares of Microbot Medical during the 2nd quarter worth approximately $45,000. Renaissance Technologies LLC grew its position in shares of Microbot Medical by 5.5% during the 2nd quarter. Renaissance Technologies LLC now owns 206,887 shares of the biotechnology company’s stock worth $1,065,000 after buying an additional 10,838 shares during the period. BlackRock Inc. increased its stake in shares of Microbot Medical by 5.7% in the 2nd quarter. BlackRock Inc. now owns 183,520 shares of the biotechnology company’s stock valued at $945,000 after acquiring an additional 9,906 shares in the last quarter. Finally, Morgan Stanley increased its stake in shares of Microbot Medical by 77.0% in the 2nd quarter. Morgan Stanley now owns 6,316 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 2,748 shares in the last quarter. 14.27% of the stock is currently owned by hedge funds and other institutional investors.

About Microbot Medical

Microbot Medical Inc, a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob and TipCAT micro-robotic technologies, is developing two product candidates, including the Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; and a self-propelling, semi-disposable endoscope, which is used in colonoscopy procedures.

Further Reading: Economic Reports

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit